Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 2
2007 5
2008 8
2009 3
2010 1
2011 4
2012 6
2013 4
2014 1
2015 2
2016 12
2017 6
2018 8
2019 5
2020 5
2021 7
2022 14
2023 15
2024 19
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Leveraging automated time-lapse microscopy coupled with deep learning to automate colony forming assay.
Klett A, Raith D, Silvestrini P, Stingl M, Bermeitinger J, Sapre A, Condor M, Melachrinos R, Kusterer M, Brand A, Pisani G, Ullrich E, Follo M, Duque-Afonso J, Mertelsmann R. Klett A, et al. Among authors: ullrich e. Front Oncol. 2025 Feb 19;15:1520972. doi: 10.3389/fonc.2025.1520972. eCollection 2025. Front Oncol. 2025. PMID: 40046624 Free PMC article.
CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma.
Moser LM, Heim C, Koschade SE, Wendel P, Bozkurt S, Harenkamp S, Kreyenberg H, Merker M, Münch C, Gradhand E, Vogler M, Ullrich E, Bönig H, Klusmann JH, Bader P, Wels WS, Rettinger E. Moser LM, et al. Among authors: ullrich e. Front Immunol. 2025 Feb 3;16:1485817. doi: 10.3389/fimmu.2025.1485817. eCollection 2025. Front Immunol. 2025. PMID: 39963129 Free PMC article.
Empowering Natural Killer Cells to Combat Acute Myeloid Leukemia: Perspective on CAR-NK Cell Therapy.
Gierschek F, Schlueter J, Kühnel I, Feigl FF, Schmiedel D, Prüfer M, Buchinger L, Cerwenka A, Cappel C, Huenecke S, Köhl U, Wels WS, Ullrich E; Translational Oncology Consortium “NKfit4AML” sponsored by the German Cancer Aid. Gierschek F, et al. Among authors: ullrich e. Transfus Med Hemother. 2024 Oct 1;52(1):42-60. doi: 10.1159/000540962. eCollection 2025 Feb. Transfus Med Hemother. 2024. PMID: 39944413 Free PMC article. Review.
Impact of inhibitory KIR ligand mismatch and other variables on outcomes following myeloablative posttransplant cyclophosphamide-based T-cell-replete haploidentical bone marrow transplantation.
Kayser S, Salzmann-Manrique E, Serve H, Bader P, Klusmann JH, Seidl C, Schwäble J, Bug G, Ullrich E. Kayser S, et al. Among authors: ullrich e. Front Immunol. 2024 Dec 16;15:1413927. doi: 10.3389/fimmu.2024.1413927. eCollection 2024. Front Immunol. 2024. PMID: 39737173 Free PMC article.
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.
Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, Hogan W, DeFilipp Z, Qayed M, Etra AM, Sandhu K, Kraus S, Olson T, Hexner E, Aguayo-Hiraldo P, Reshef R, Ullrich E, Schechter T, Kitko C, Chanswangphuwana C, Merli P, Akahoshi Y, Baez J, Eng G, Beheshti R, Kowalyk S, Morales G, Louloudis IE, Young R, Holler E, Nakamura R, Ferrara JLM, Levine JE. Katsivelos N, et al. Among authors: ullrich e. Transplant Cell Ther. 2025 Jan;31(1):10.e1-10.e9. doi: 10.1016/j.jtct.2024.10.012. Epub 2024 Dec 11. Transplant Cell Ther. 2025. PMID: 39667999
CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.
Bexte T, Albinger N, Al Ajami A, Wendel P, Buchinger L, Gessner A, Alzubi J, Särchen V, Vogler M, Rasheed HM, Jung BA, Wolf S, Bhayadia R, Oellerich T, Klusmann JH, Penack O, Möker N, Cathomen T, Rieger MA, Imkeller K, Ullrich E. Bexte T, et al. Among authors: ullrich e. Nat Commun. 2024 Sep 30;15(1):8439. doi: 10.1038/s41467-024-52388-1. Nat Commun. 2024. PMID: 39349459 Free PMC article.
CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients.
Zöphel S, Küchler N, Jansky J, Hoxha C, Schäfer G, Weise JJ, Vialle J, Kaschek L, Stopper G, Eichler H, Yildiz D, Moter A, Wendel P, Ullrich E, Schormann C, Rixecker T, Cetin O, Neumann F, Orth P, Bewarder M, Hoth M, Thurner L, Schwarz EC. Zöphel S, et al. Among authors: ullrich e. Mol Cancer. 2024 Sep 28;23(1):210. doi: 10.1186/s12943-024-02123-7. Mol Cancer. 2024. PMID: 39342291 Free PMC article.
Editorial: Women in cancer immunity and immunotherapy.
Yao M, Ullrich E, Albini A. Yao M, et al. Among authors: ullrich e. Front Immunol. 2024 Aug 21;15:1466010. doi: 10.3389/fimmu.2024.1466010. eCollection 2024. Front Immunol. 2024. PMID: 39234252 Free PMC article. No abstract available.
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients.
Rios CAO, Qayed M, Etra AM, Reshef R, Newcomb R, Yuhasz N, Hexner EO, Aguayo-Hiraldo P, Merli P, Hogan WJ, Weber D, Kitko CL, Ayuk F, Eder M, Grupp SA, Kraus S, Sandhu K, Ullrich E, Vasova I, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Louloudis IE, Morales G, Spyrou N, Young R, Nakamura R, Levine JE, Ferrara JLM, Akahoshi Y. Rios CAO, et al. Among authors: ullrich e. Transplant Cell Ther. 2024 Nov;30(11):1061.e1-1061.e10. doi: 10.1016/j.jtct.2024.08.019. Epub 2024 Sep 1. Transplant Cell Ther. 2024. PMID: 39222793
117 results